- Home
- RXO vs PHVS Comparison
RXO vs PHVS Comparison
Compare RXO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXO | PHVS |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RXO | PHVS |
|---|---|---|
| Price | $18.17 | $30.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 11 |
| Target Price | $16.33 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.7M | 251.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,742,000,000.00 | N/A |
| Revenue This Year | $0.49 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $10.43 | $15.51 |
| 52 Week High | $20.38 | $31.14 |
Technical Indicators
Market Signals| Indicator | RXO | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 56.73 |
| Support Level | $16.17 | $24.73 |
| Resistance Level | $18.69 | N/A |
| Average True Range (ATR) | 0.96 | 1.58 |
| MACD | -0.18 | 0.10 |
| Stochastic Oscillator | 42.27 | 74.83 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.